Key Takeaways
- Most large employer commercial plans cover Wegovy with prior authorization if your BMI is at least 30, or 27 with a weight-related condition.
- Medicare Part D does not cover Wegovy for weight loss alone, but as of March 2024 it covers Wegovy when prescribed to reduce cardiovascular risk in adults with established heart disease and obesity or overweight.
- Medicaid coverage varies by state. About 16 states cover Wegovy for weight loss as of early 2026, and another 10 cover it case by case.
- Employer plans that opt into the "weight loss exclusion" rider do not cover Wegovy or any anti-obesity medication. About 43% of large employers carve weight-loss drugs out of pharmacy benefits per Mercer's 2025 survey.
- The Novo Nordisk savings card can drop commercial-insurance copays as low as $0 to $25 per month for eligible patients, though most patients pay $25 to $200.
Direct answer (40-60 words)
Wegovy is covered by most large employer commercial plans, some marketplace plans, Medicare Part D for cardiovascular risk reduction in qualifying patients, and a minority of state Medicaid programs. Coverage requires prior authorization, a BMI of 30 or 27 with a comorbidity, and documented diet-and-exercise efforts. About 43% of large employers exclude all weight-loss drugs.
Table of contents
- The 30-second answer
- How insurance categorizes Wegovy
- Commercial employer plans: what's covered, what isn't
- Marketplace and individual plans
- Medicare and the 2024 cardiovascular indication
- Medicaid coverage by state
- The prior authorization process, step by step
- The weight-loss exclusion rider explained
- Real copay scenarios
- The Novo Nordisk savings card
- What to do when coverage is denied
- The compounded semaglutide alternative
- FAQ
- Sources
- Footer disclaimers
How insurance categorizes Wegovy
Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. In March 2024 the FDA expanded the label to include reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial (Lincoff et al., NEJM 2023).
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Insurers classify Wegovy as a specialty injectable. Most plans place it on Tier 3 (non-preferred brand) or Tier 4 (specialty), which means coinsurance of 20 to 40 percent rather than a flat copay. Some plans put it on Tier 2 if they have a negotiated contract with Novo Nordisk.
Whether your plan covers it at all depends on your employer's choice of pharmacy benefit design. Two plans from the same insurer can have totally different Wegovy rules.
Commercial employer plans: what's covered, what isn't
Most large employer plans cover Wegovy if three conditions are met: the patient meets the FDA BMI thresholds, prior authorization is approved, and the employer's plan includes anti-obesity medications.
Common commercial plan rules in 2026:
- BMI requirement: 30 or higher, or 27 or higher with a comorbidity documented in the chart.
- Documented attempt at lifestyle intervention for at least 3 to 6 months before approval.
- Step-therapy requirement on some plans: try a cheaper drug first (often phentermine or naltrexone-bupropion).
- Annual reauthorization showing at least 5 percent weight loss after 6 months.
- Prescriber type restriction on some plans: written by a primary care provider, endocrinologist, or board-certified obesity medicine clinician.
A 2025 Mercer survey of 1,800 large employers found 57 percent covered GLP-1 anti-obesity medications, up from 41 percent in 2023. The same survey found that 43 percent of employers either explicitly excluded these drugs or were considering exclusion at the next plan year because of cost. Average per-member-per-month spend on GLP-1s reached $36 in 2024 versus $9 in 2022 (Mercer 2025).
If your plan does cover Wegovy, the typical patient out-of-pocket cost runs $25 to $200 per month after the deductible is met. Without the savings card, average commercial copays in 2025 were $158 per month per Komodo Health claims data.
Marketplace and individual plans
Marketplace plans (Healthcare.gov silver, gold, and platinum plans) sometimes cover Wegovy and sometimes don't, depending on the carrier and state. The Affordable Care Act doesn't require coverage of weight-loss drugs.
State-by-state pattern as of early 2026:
- Several blue states (CA, NY, MA, OR, WA) require marketplace plans to cover at least one anti-obesity GLP-1.
- Most other states leave it to insurer discretion.
- Even when covered, marketplace plans often place Wegovy on Tier 4 with 30 to 40 percent coinsurance after deductible. With a $4,000 deductible and a $1,350 monthly retail price, the first several fills can run full retail until the deductible is met.
A practical approach for marketplace shoppers: search for the carrier's formulary online before enrolling. Look up "semaglutide" and "Wegovy" specifically. Plans that cover both Wegovy and Ozempic on Tier 2 are rare and worth identifying.
Medicare and the 2024 cardiovascular indication
Medicare Part D historically did not cover any drug used for weight loss. The Medicare Modernization Act of 2003 explicitly excludes weight-loss medications from Part D coverage.
The picture changed in March 2024. The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who also have obesity (BMI 30+) or overweight (BMI 27+). Because this is now a non-weight-loss indication, CMS issued guidance allowing Part D plans to cover Wegovy for this purpose. Plans began adding coverage in mid-2024.
To qualify for Medicare Part D coverage of Wegovy in 2026:
- Established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease).
- BMI of 27 or higher.
- Prior authorization documenting the cardiovascular indication.
- Prescription written for cardiovascular risk reduction, not weight loss.
If you have Medicare and obesity but no cardiovascular disease, Wegovy is still not covered for weight loss. The Treat and Reduce Obesity Act, which would expand Medicare coverage to all obesity, has been introduced in Congress but has not passed as of April 2026.
Medicare Part D specialty copays for Wegovy in 2026 typically run $200 to $500 per month and patients are not eligible for the Novo Nordisk savings card.
Medicaid coverage by state
State Medicaid programs each set their own rules for anti-obesity medications. Coverage is patchy.
States that cover Wegovy for weight loss as of early 2026 include California, Connecticut, Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, New Hampshire, New Jersey, North Carolina, Pennsylvania, Rhode Island, Virginia, Wisconsin, and Washington DC. Most require prior authorization with BMI 30+, comorbidity documentation, and a 6-month lifestyle intervention attempt.
States with conditional or limited coverage include New York, Texas, Florida, Georgia, and Illinois. These states cover Wegovy for some patient populations (often pregnant patients with gestational risk factors or patients with severe obesity-related complications) but not as a general weight-loss benefit.
States that do not cover Wegovy at all for weight loss include most southern and mountain-west states. Medicaid will still cover Ozempic if prescribed for type 2 diabetes in nearly every state.
The most reliable source for your state's current rule is the Medicaid preferred drug list (PDL) on your state's Medicaid website. Search the PDL for "semaglutide" and check the criteria.
The prior authorization process, step by step
For nearly every plan that covers Wegovy, prior authorization is required. The process usually takes 3 to 14 days.
Step 1. Your provider verifies you meet the FDA criteria: BMI 30+, or BMI 27+ with a documented comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.
Step 2. Your provider documents prior weight-loss attempts in the chart. Most plans want to see at least 3 to 6 months of structured diet and exercise, sometimes with a participating dietitian or a behavioral weight-loss program.
Step 3. Your provider submits the PA form to your insurance plan, including labs (A1C, lipid panel, BMP), the comorbidity diagnosis codes, and the lifestyle intervention notes.
Step 4. The plan reviews and approves, denies, or requests more information. Approval rates run roughly 60 to 70 percent on first submission per insurance industry data. Denials can be appealed.
Step 5. Approved PAs are typically valid for 6 to 12 months. Renewal usually requires evidence of clinical response, defined as at least 5 percent weight loss from baseline at 6 months. If you haven't lost 5 percent, the plan can decline reauthorization.
The 5-percent threshold comes directly from the Wegovy prescribing information, which states the medication should be discontinued if a patient has not lost at least 5 percent of body weight at 6 months. Insurers use this as the standard renewal criterion.
The weight-loss exclusion rider explained
Many large employer plans actively exclude weight-loss drugs from pharmacy coverage even when the underlying insurance carrier offers them. This is called a "weight-loss exclusion rider" and it sits in the plan document, not on the insurance company's formulary.
Why employers use the exclusion: Wegovy at $1,350 per month per patient adds substantial cost. An employer with 1,000 covered lives where 5 percent use Wegovy spends roughly $810,000 per year just on this one drug. Some employers carve it out, others negotiate aggressive PA criteria.
How to find out if your plan has the exclusion:
- Read your Summary Plan Description (SPD) under "Exclusions" or "Limitations." Search for "weight loss," "obesity," "anti-obesity," or "GLP-1."
- Call your plan member services and ask: "Does my pharmacy benefit cover semaglutide for weight management or only for diabetes?"
- Have your provider submit a "test claim" for Wegovy at a pharmacy. The pharmacy claim system returns the actual coverage rule.
If the rider applies, no amount of prior authorization will change the answer. The drug is excluded by plan design, not by clinical criteria. Your options become Wegovy out of pocket, the savings card if eligible, the patient assistance program, or compounded semaglutide.
Real copay scenarios
To make the coverage rules concrete, here are five anonymized scenarios.
| Scenario | Plan | Coverage outcome | Monthly cost |
|---|---|---|---|
| Fortune 500 PPO | Tier 2, BMI 33, comorbidity | PA approved | $50 copay |
| Marketplace silver | Tier 4, BMI 31 | PA approved, deductible not met | $1,350 first 3 fills, then 30% coinsurance |
| Medicare Part D | BMI 28, prior MI | PA approved on cardiovascular indication | $250 specialty copay |
| Texas Medicaid | BMI 35, hypertension | Wegovy for weight loss not covered | Out of pocket |
| Mid-sized employer with rider | BMI 32, sleep apnea | Plan excludes anti-obesity drugs | Out of pocket |
The pattern: coverage is real but uneven, and the same patient can have a $50 month or a $1,350 month depending only on which plan they're on.
The Novo Nordisk savings card
Novo Nordisk's WeGoTogether savings card is the manufacturer copay assistance program for Wegovy.
Eligibility:
- Commercial insurance that covers Wegovy.
- U.S. resident.
- Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded plan.
What it does:
- Drops eligible commercial-insurance copays to as little as $0 per month for some patients with a maximum benefit of approximately $225 per fill.
- For cash-pay patients with commercial insurance that does not cover Wegovy, the card offers Wegovy at approximately $499 per month through select pharmacies.
What it doesn't do:
- Help anyone on Medicare or Medicaid.
- Override a plan exclusion rider.
- Apply to compounded semaglutide.
Patients enrolled in the savings program in 2025 paid an average of $25 to $50 per month according to Novo Nordisk's investor disclosures.
What to do when coverage is denied
A first-pass denial is not the end of the road. Several layers of appeal exist.
Internal appeal. Within 30 to 60 days of the denial, your provider submits an internal appeal with additional clinical documentation. Common winning evidence: prior failed weight-loss attempts, comorbidity progression, documented obesity-related complications, peer-reviewed support for the medication.
Peer-to-peer review. Your provider speaks directly with the insurance company's medical reviewer. Approval rates on peer-to-peer review are notably higher than on paper appeals.
External review. If internal appeals fail, every state allows an independent external review by a third party. Filing deadlines vary by state but are usually 60 to 180 days after the final internal denial.
Switch to the cardiovascular indication. If you have established cardiovascular disease, your provider can submit a new PA under the SELECT-trial cardiovascular indication. Some plans approve under this label even when they deny under the weight-loss label.
Use the manufacturer cash program. The $499 cash program through participating pharmacies bypasses the insurance question entirely.
Switch products. If Wegovy is denied but Zepbound is on your formulary, your provider can prescribe Zepbound (tirzepatide) instead. Plans that exclude Wegovy sometimes cover Zepbound and vice versa.
The compounded semaglutide alternative
For patients whose plan excludes Wegovy, denies after appeal, or whose copay is unsustainable, compounded semaglutide is the most common alternative.
Compounded semaglutide is prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not the same product as Wegovy. Compounding for weight management is permitted only under specific FDA conditions, primarily when there is a clinical reason an FDA-approved product cannot be used for an individual patient.
Pricing for compounded semaglutide programs typically runs $179 to $279 per month flat, regardless of insurance.
When compounded makes sense:
- Your insurance excludes Wegovy entirely.
- Your copay is unaffordable and you don't qualify for the savings card.
- You want predictable monthly pricing without insurance paperwork.
When brand-name Wegovy makes more sense:
- Your copay is under $100 per month with the savings card.
- You want an FDA-approved product with a pre-filled pen.
- You qualify for the patient assistance program and can get Wegovy free or very low cost.
The decision should be made with a licensed clinician who can review your specific plan, BMI, comorbidities, and clinical history. (See our Wegovy cost guide and compounded semaglutide pricing.)
FAQ
Does Blue Cross Blue Shield cover Wegovy for weight loss? Most BCBS plans cover Wegovy for weight loss when the patient meets BMI 30+ (or 27+ with a comorbidity), prior authorization is approved, and the employer hasn't carved out anti-obesity drugs from the plan. Coverage details vary by state plan and employer group. Call member services or read your SPD to confirm.
Does Aetna cover Wegovy? Aetna's national formulary includes Wegovy on Tier 3 with prior authorization for most commercial plans. Step therapy may apply: some plans require a documented trial of phentermine or other anti-obesity drugs first. Self-funded employer plans through Aetna can opt out via the weight-loss exclusion rider.
Does Cigna cover Wegovy? Cigna covers Wegovy on most commercial plans with prior authorization, BMI documentation, and a 6-month lifestyle intervention attempt. Cigna's Express Scripts pharmacy benefit handles the PA process. Reauthorization at 6 months requires documented 5 percent weight loss.
Does United Healthcare cover Wegovy? UHC covers Wegovy on most commercial plans with prior authorization. OptumRx handles PA submission and decisioning. UHC employer plans frequently use the weight-loss exclusion rider, so coverage depends heavily on which UHC plan you have.
Does Medicare cover Wegovy? Medicare Part D covers Wegovy only for cardiovascular risk reduction in patients with established cardiovascular disease plus BMI 27+. Medicare does not cover Wegovy for weight loss alone. Coverage for weight loss is barred by federal statute and would require an act of Congress to change.
Does Medicaid cover Wegovy? Coverage varies by state. About 16 state Medicaid programs cover Wegovy for weight loss with prior authorization, another 10 cover it case by case, and roughly 24 states do not cover it for weight loss. Check your state Medicaid preferred drug list for current rules.
What BMI do I need for insurance to cover Wegovy? The FDA label requires a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Most insurance plans use these same thresholds for prior authorization.
What if my insurance denies Wegovy? File an internal appeal with additional clinical documentation, request a peer-to-peer review between your provider and the plan's medical reviewer, file an external review through your state's independent review process, switch to the cardiovascular indication if you have qualifying heart disease, or consider the manufacturer cash program at approximately $499 per month or compounded semaglutide.
Will insurance cover Wegovy for prediabetes? Most plans do not cover Wegovy for prediabetes alone. Prediabetes is not on the FDA label. If you have prediabetes plus BMI 30+ (or 27+ with another comorbidity such as hypertension), the BMI plus comorbidity criteria can support a PA.
How much is Wegovy with insurance? With commercial insurance that covers Wegovy and the savings card, the typical out-of-pocket cost is $0 to $50 per month. Without the savings card, $25 to $200 per month is common after the deductible is met. With Medicare Part D, $200 to $500 per month is typical. Without coverage, retail is roughly $1,350 per month.
Is Wegovy cheaper than Ozempic? Wegovy and Ozempic have similar list prices ($1,350 vs $1,000 monthly). The difference between them is the indication, not the price. Ozempic is cheaper to access for most patients only because more insurance plans cover it for diabetes than cover Wegovy for weight loss.
Can I switch from Ozempic to Wegovy if my insurance covers Ozempic but not Wegovy? You and your prescriber can request the switch, but if your plan excludes anti-obesity drugs the change won't be covered. Some patients in this situation stay on Ozempic if they have type 2 diabetes (covered) and use the savings card or patient assistance to manage cost.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Wegovy (semaglutide) injection prescribing information. Novo Nordisk Inc. 2024.
- U.S. Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems in adults with obesity or overweight. Press release, March 8, 2024.
- Centers for Medicare & Medicaid Services. Memo on Part D coverage of anti-obesity drugs with FDA-approved cardiovascular indications. March 2024.
- Mercer. National Survey of Employer-Sponsored Health Plans. 2025.
- Komodo Health. Real-world copay analysis of GLP-1 anti-obesity drugs. 2025 claims database report.
- Kaiser Family Foundation. Medicaid coverage of GLP-1 medications: state-by-state analysis. 2025.
- American Medical Association. Treat and Reduce Obesity Act: legislative status update. 2026.
- Novo Nordisk. WeGoTogether savings program terms and conditions. 2026.
- NIDDK. Prescription medications to treat overweight and obesity. National Institute of Diabetes and Digestive and Kidney Diseases. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →